MedTrace Logo

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

NCT01386164 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2013-08-16

No results posted yet for this study

Summary

The purpose of this study is to analyze and compare the immunogenicity of Bivalent and Tetravalent vaccines against Human Papillomavirus in HIV-infected adult persons.

Conditions

  • HIV
  • Human Papillomavirus

Interventions

BIOLOGICAL

Gardasil

Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

BIOLOGICAL

Cervarix

Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars Østergaard, MD,PhD,DmSC · Department of Infectious Diseases, Aarhus University Hospital, Denmark

  • Lars Toft, MD · Department of Infectious Diseases, Aarhus University Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-12-31
Completion
2013-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01386164 on ClinicalTrials.gov